Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Han-Mou Tsai

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Seminars in Thrombosis and Hemostasis|November 25, 2003
Shear stress and von Willebrand factor in health and diseaseHan-Mou Tsai
International Journal of Hematology|January 9, 2010
Pathophysiology of thrombotic thrombocytopenic purpuraHan-Mou Tsai
Kidney International|February 2, 2010
Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time?Han-Mou Tsai
Transfusion|November 8, 2002
Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpuraHan-Mou Tsai
Kidney International. Supplement|January 31, 2009
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpuraHan-Mou Tsai
Transfusion Medicine Reviews|October 5, 2014
A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndromeHan-Mou Tsai
International Review of Thrombosis|October 20, 2015
Measurement of ADAMTS13Han-Mou Tsai
Journal of Molecular Medicine (Berlin, Germany)|October 24, 2002
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraHan-Mou Tsai
Nihon Kessen Shiketsu Gakkai Shi = Japanese Journal of Thrombosis and Hemostasis|June 29, 2011
Why Do We Need ADAMTS13?Han-Mou Tsai
Journal of Clinical Hypertension (Greenwich, Conn.)|September 12, 2015
Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension?Han-Mou Tsai
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Seminars in Thrombosis and Hemostasis|November 25, 2003
Shear stress and von Willebrand factor in health and diseaseHan-Mou Tsai
International Journal of Hematology|January 9, 2010
Pathophysiology of thrombotic thrombocytopenic purpuraHan-Mou Tsai
Kidney International|February 2, 2010
Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time?Han-Mou Tsai
Transfusion|November 8, 2002
Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpuraHan-Mou Tsai
Kidney International. Supplement|January 31, 2009
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpuraHan-Mou Tsai
Transfusion Medicine Reviews|October 5, 2014
A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndromeHan-Mou Tsai
International Review of Thrombosis|October 20, 2015
Measurement of ADAMTS13Han-Mou Tsai
Journal of Molecular Medicine (Berlin, Germany)|October 24, 2002
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraHan-Mou Tsai
Nihon Kessen Shiketsu Gakkai Shi = Japanese Journal of Thrombosis and Hemostasis|June 29, 2011
Why Do We Need ADAMTS13?Han-Mou Tsai
Journal of Clinical Hypertension (Greenwich, Conn.)|September 12, 2015
Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension?Han-Mou Tsai
Pageof 6